Tests two new drugs together in men with advanced prostate cancer
Tests JNJ-78278343 with JNJ-95298177 in adults with metastatic castration-resistant prostate cancer.
Key facts
- Who runs it
- Janssen Research & Development, LLC
- Where
- Cleveland, New York, Sarasota, and Seattle, United StatesSee the 4 sitesAlso in 1 other country, 2 sites
- Trial code
- Registry title
- A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 140 people, planned
- Started
- 7 Jul 2025
- Expected to end
- 30 Dec 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- JNJ-78278343
- JNJ-95298177
- JNJ-87189401
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 18 or older with prostate cancer that has spread and no longer responds to hormone-lowering treatment (mCRPC).
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Adenocarcinoma of the prostate that has spread (metastatic) and is castration-resistant (mCRPC), with measurable or evaluable disease. Small cell, carcinoid and neuroendocrine cancers of the prostate are not allowed; adenocarcinoma with some neuroendocrine features is allowed.
- Earlier treatment
- Must have had orchiectomy or medical castration, or be on ongoing androgen deprivation therapy with a GnRH analog and continue it during treatment. Prior PSMA radioligand therapy is allowed in Part 1 and required in Part 2C and 2D (last dose more than 3 months before), but it is not allowed in Part 2A and 2B. Prior KLK2-targeted therapy, and prior antibody drug conjugates with microtubule inhibitor payloads, are not allowed.
- Biomarker or test result
- PSA of at least 2 ng/mL at screening.
Main reasons for not taking part
- Any anti-cancer or investigational treatment within 14 days before the first dose
- T-cell redirecting treatment within 90 days, or immune checkpoint inhibitors within 6 weeks, before the first dose
- Side effects from earlier cancer treatment not back to grade 1 or baseline (except hair loss and vitiligo)
- Brain metastases or leptomeningeal disease, unless treated, stable and symptom-free for more than 2 weeks and off corticosteroids for at least 2 weeks
- Known allergy to any component of JNJ-78278343, JNJ-95298177 or JNJ-87189401
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Histologically confirmed adenocarcinoma of the prostate. Primary small cell carcinoma, carcinoid tumor, neuroendocrine (NE) carcinoma, or large cell NE carcinoma arising in the prostate are not allowed; however, adenocarcinomas with NE features (for example [e.g.], immunohistochemistry [IHC] with both androgen receptor [AR]- and NE-marker positivity) are allowed
- Must have metastatic castration-resistant prostate cancer (mCRPC)
- PSA must measure at least 2 nanograms per milliliters (ng/mL) at screening
- Measurable or evaluable disease
- Prior orchiectomy or medical castration; or, for participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) analog (agonist or antagonist) prior to the first dose of study drug and must continue this therapy throughout the treatment phase
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Who cannot take part
- Toxicity related to prior anticancer therapy that has not returned to grade less than or equal to (<=) 1 or baseline levels (except for alopecia and vitiligo)
- Participants with leptomeningeal disease or brain metastases, with the exception of participants with definitively, locally treated brain metastases that are clinically stable and asymptomatic greater than (>) 2 weeks, and who are off corticosteroid treatment for at least 2 weeks prior to first dose of study treatment
- Treatment with any anti-cancer or investigational agents within 14 days prior to the first dose of study treatment; specific requirements for certain anti-cancer therapies are as follows:; Any T-cell redirecting treatment (e.g., CD3-directed bispecific or Chimeric Antigen Receptor T-cell [CAR-T] therapy) within 90 days prior to the first dose of study treatment; Immune checkpoint inhibitors within 6 weeks prior to the first dose of study treatment; Radium (Ra) 223 dichloride within 28 days prior to the first dose of study treatment; Any prior treatment with kallikrein-related peptidase 2 (KLK2)-targeted therapy; Any prior prostate-specific membrane antigen (PSMA)-targeting therapy (that is [i.e.], participants who received PSMA-targeting radioconjugates are excluded) [Parts 2A and 2B only]. Prior PSMA RLT is allowed in Part 1 and required for Part 2C and Part 2D but last dose must be >3 months prior to the first dose of study treatment; Any prior antibody drug conjugates (ADCs) with microtubule inhibitor payloads (e.g., auristatins, maytansinoids, tubulysins)
- Known allergies, hypersensitivity, or intolerance to any of the components (e.g., excipients) of JNJ-78278343, JNJ-95298177, or JNJ-87189401
- Any serious underlying medical conditions or other issue that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site to understand the informed consent, or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments
Where in United States
Also in 1 other country, 2 sites
- University Hospitals Cleveland Medical Center*Cleveland, United StatesTaking people
- Columbia University Medical CenterNew York, United StatesTaking people
- Florida Cancer SpecialistsSarasota, United StatesTaking people
- Fred Hutchinson Cancer CenterSeattle, United StatesTaking people
About the trial
What the trial wants to find out
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the RP2CD of JNJ-7827834 and JNJ-95298177 with or without JNJ-87189401 is for treatment of participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of prostate cancer where the cancer has spread beyond the prostate and is resistant to hormonal therapy) in Part 2 (Dose expansion) of study.
The 2 groups in the trial
- Part 1: Dose ConfirmationTreatment being tested
Participants will receive JNJ-78278343 in combination with JNJ-95298177 in a dose de-escalation schedule in accordance with the Bayesian Optimal Interval Design (BOIN) design to determine the recommended phase 2 combination dose (RP2CD) regimen.
Treatment: JNJ-78278343 and JNJ-95298177
- Part 2: Dose ExpansionTreatment being tested
Participants will receive JNJ-78278343 in combination with JNJ-95298177 at the RP2CD as determined in Part 1 of the study with or without JNJ-87189401 to confirm the safety and anti-tumor activity.
Treatment: JNJ-78278343, JNJ-95298177, and JNJ-87189401
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-95298177, an Antibody Drug Conjugate Targeting Prostate Specific Membrane Antigen, for Prostate Cancer
- Plain-language title
- Tests two new drugs together in men with advanced prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 November 2026